Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Oral Investigations
Published in: Clinical Oral Investigations 6/2012

01-12-2012 | Original Article

Investigation of trefoil factor expression in saliva and oral mucosal tissues of patients with oral squamous cell carcinoma

Authors: Ponlatham Chaiyarit, Akasith Utrawichian, Chanvit Leelayuwat, Patrawut Vatanasapt, Nattharee Chanchareonsook, Mie Hessellund Samson, Andrew S. Giraud

Published in: Clinical Oral Investigations | Issue 6/2012

Login to get access

Abstract

Objectives

The aims of our study were to determine levels of trefoil factor (TFF) peptides in saliva and oral mucosal tissues from patients with oral squamous cell carcinoma (OSCC), and to evaluate whether individual members of TFFs (TFF1, TFF2, and TFF3) might act as biomarkers of disease.

Materials and methods

Saliva samples were from 23 healthy subjects and 23 OSCC patients. Tissue samples were collected from 32 normal oral mucosa (NOM) and 32 OSCC biopsy specimens. ELISA and immunohistochemical methods were used to evaluate the expression of TFF1, TFF2, and TFF3 in saliva and oral mucosal tissues, respectively.

Results

Expression of TFF2 and TFF3 in oral mucosal tissues of OSCC patients was strongly downregulated when compared to healthy subjects (p < 0.001 and p = 0.002, respectively). However, there were no differences in levels of salivary TFF concentrations between OSCC patients and healthy subjects.

Conclusions

The present study extends previous observations, demonstrating the reduction of TFF2 and TFF3 expression in oral mucosal tissues of OSCC patients.

Clinical relevance

These findings suggest the clinical significance of TFF2 and TFF3 molecules as negative markers of tumor progression in OSCC. Quantification of TFF levels in saliva may not be optimal in terms of diagnostic or predictive value for OSCC derived from oral mucosa.
Literature
1.
Mori K, Fujii R, Kida N, Takahashi H, Ohkubo S, Fujino M, Ohta M, Hayashi K (1990) Complete primary structure of the human estrogen responsive gene (pS2) product. J Biochem 107:73–6PubMed
2.
Tomasetto C, Rio M, Gautier C, Wolf C, Hareuveni M, Chambon P, Lathe R (1990) hSP, the domain-duplicated homolog of pS2 protein, is co-expressed with pS2 in the stomach but not in breast carcinoma. EMBO J 9:407–14PubMed
3.
Hauser F, Poulsom R, Chinery R, Rogers LA, Hanby AM, Wright NA, Hoffmann W (1993) hP1.B, a human P-domain peptide homologous with rat intestinal trefoil factor, is expressed also in the ulcer-associated cell lineage and the uterus. Proc Natl Acad Sci USA 90:6961–65PubMedCrossRef
4.
Thim L, May FEB (2005) Structure of mammalian trefoil factors and functional insights. Cell Mol Life Sci 62:2956–73PubMedCrossRef
5.
Chinery R, Williamson J, Poulsom R (1996) The gene encoding human intestinal trefoil factor (TFF3) is located on chromosome 21q22.3 clustered with other members of the trefoil peptide family. Genomics 32:281–4PubMedCrossRef
6.
Madsen J, Nielsen O, Tornøe I, Thim L, Holmskov U (2007) Tissue localization of human trefoil factors 1, 2, and 3. J Histochem Cytochem 55:505–13PubMedCrossRef
7.
Jagla W, Wiede A, Dietzmann K, Rutkowski K, Hoffmann W (2000) Co-localization of TFF3 peptide and oxytocin in the human hypothalamus. FASEB J 14:1126–31PubMed
8.
Paulsen FP, Hinz M, Schaudig U, Thale AB, Hoffmann W (2002) TFF peptides in the human efferent tear ducts. Invest Ophthalmol Vis Sci 43:3359–64PubMed
9.
Jagla W, Wiede A, Hinz M, Dietzmann K, Gülicher D, Gerlach KL, Hoffmann W (1999) Secretion of TFF-peptides by human salivary glands. Cell Tissue Res 298:161–6PubMedCrossRef
10.
Devine DA, High AS, Owen PJ, Poulsom R, Bonass WA (2000) Trefoil factor expression in normal and diseased human salivary glands. Hum Pathol 31:509–15PubMedCrossRef
11.
Kouznetsova I, Gerlach KL, Zahl C, Hoffmann W (2010) Expression analysis of human salivary glands by laser microdissection: differences between submandibular and labial glands. Cell Physiol Biochem 26:375–82PubMedCrossRef
12.
Kutta H, May J, Jaehne M, Münscher A, Paulsen FP (2006) Antimicrobial defence mechanisms of the human parotid duct. J Anat 208:609–19PubMedCrossRef
13.
dos Santos SE, Ulrich M, Döring G, Botzenhart K, Gött P (2000) Trefoil factor family domain peptides in the human respiratory tract. J Pathol 190:133–42CrossRef
14.
Cook GA, Familari M, Thim L, Giraud AS (1999) The trefoil peptides TFF2 and TFF3 are expressed in rat lymphoid tissues and participate in the immune response. FEBS Lett 456:155–9PubMedCrossRef
15.
Srivatsa G, Giraud AS, Ulaganathan M, Yeomans ND, Dow C, Nicoll AJ (2002) Biliary epithelial trefoil peptide expression is increased in biliary diseases. Histopathology 40:261–8PubMedCrossRef
16.
Wiede A, Hinz M, Canzler E, Franke K, Quednow C, Hoffmann W (2001) Synthesis and localization of the mucin-associated TFF-peptides in the human uterus. Cell Tissue Res 303:109–15PubMedCrossRef
17.
Vestergaard EM, Poulsen SS, Grønbaek H, Larsen R, Nielsen AM, Ejskjaer K, Clausen JT, Thim L, Nexø E (2002) Development and evaluation of an ELISA for human trefoil factor 3. Clin Chem 48:1689–95PubMed
18.
Vestergaard EM, Brynskov J, Ejskjaer K, Clausen JT, Thim L, Nexø E, Poulsen SS (2004) Immunoassays of human trefoil factors 1 and 2: measured on serum from patients with inflammatory bowel disease. Scand J Clin Lab Invest 64:146–56PubMedCrossRef
19.
Vestergaard EM, Nexø E, Wendt A, Guthmann F (2008) Trefoil factors in human milk. Early Hum Dev 84:631–5PubMedCrossRef
20.
Kouznetsova I, Peitz U, Vieth M, Meyer F, Vestergaard EM, Malfertheiner P, Roessner A, Lippert H, Hoffmann W (2004) A gradient of TFF3 (trefoil factor family 3) peptide synthesis within the normal human gastric mucosa. Cell Tissue Res 316:155–65PubMedCrossRef
21.
Rasmussen TN, Thim L, Raaberg L, Harling H, Holst JJ (1990) Pancreatic spasmolytic polypeptide, a potential growth factor for the intestine: neural control of secretion. Digestion 46:226–31PubMedCrossRef
22.
Rasmussen TN, Harling H, Thim L, Pierzynowski S, Weström BR, Holst JJ (1993) Regulation of secretion of pancreatic spasmolytic polypeptide from porcine pancreas. Am J Physiol 264:22–9
23.
Miyashita S, Nomoto H, Konishi H, Hayashi K (1994) Estimation of pS2 protein level in human body fluids by a sensitive two-site enzyme immunoassay. Clin Chim Acta 228:71–81PubMedCrossRef
24.
Goldenring JR, Poulsom R, Ray GS, Wright N, Meise KS, Coffey RJ Jr (1996) Expression of trefoil peptides in the gastric mucosa of transgenic mice overexpressing transforming growth factor-alpha. Growth Factors 13:111–9PubMedCrossRef
25.
Taupin D, Wu DC, Jeon WK, Devaney K, Wang TC, Podolsky DK (1999) The trefoil gene family are coordinately expressed immediate-early genes: EGF receptor- and MAP kinase-dependent interregulation. J Clin Invest 103:31–8CrossRef
26.
Jackerott M, Lee YC, Møllgård K, Kofod H, Jensen J, Rohleder S, Neubauer N, Gaarn LW, Lykke J, Dodge R, Dalgaard LT, Søstrup B, Jensen DB, Thim L, Nexø E, Thams P, Bisgaard HC, Nielsen JH (2006) Trefoil factors are expressed in human and rat endocrine pancreas: differential regulation by growth hormone. Endocrinology 147:5752–9PubMedCrossRef
27.
Tu S, Chi AL, Lim S, Cui G, Dubeykovskaya Z, Ai W, Fleming JV, Takaishi S, Wang TC (2007) Gastrin regulates the TFF2 promoter through gastrin-responsive cis-acting elements and multiple signaling pathways. Am J Physiol Gastrointest Liver Physiol 292:1726–37CrossRef
28.
Nikolaidis NM, Zimmermann N, King NE, Mishra A, Pope SM, Finkelman FD, Rothenberg ME (2003) Trefoil factor-2 is an allergen-induced gene regulated by Th2 cytokines and STAT6 in the lung. Am J Respir Cell Mol Biol 29:458–64PubMedCrossRef
29.
Dossinger V, Kayademir T, Blin N, Gött P (2002) Down-regulation of TFF expression in gastrointestinal cell lines by cytokines and nuclear factors. Cell Physiol Biochem 12:197–206PubMedCrossRef
30.
Van De Bovenkamp JH, Korteland-Van Male AM, Büller HA, Einerhand AW, Dekker J (2005) Infection with Helicobacter pylori affects all major secretory cell populations in the human antrum. Dig Dis Sci 50:1078–86CrossRef
31.
Fox JG, Rogers AB, Whary MT, Ge Z, Ohtani M, Jones EK, Wang TC (2007) Accelerated progression of gastritis to dysplasia in the pyloric antrum of TFF2 −/− C57BL6 x Sv129 Helicobacter pylori-infected mice. Am J Pathol 171:1520–8PubMedCrossRef
32.
Tebbutt NC, Giraud AS, Inglese M, Jenkins B, Waring P, Clay FJ, Malki S, Alderman BM, Grail D, Hollande F, Heath JK, Ernst M (2002) Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 8:1089–97PubMedCrossRef
33.
Baus-Loncar M, Giraud AS (2005) Multiple regulatory pathways for trefoil factor (TFF) genes. Cell Mol Life Sci 62:2921–31PubMedCrossRef
34.
Playford RJ, Marchbank T, Chinery R, Evison R, Pignatelli M, Boulton RA, Thim L, Hanby AM (1995) Human spasmolytic polypeptide is a cytoprotective agent that stimulates cell migration. Gastroenterology 108:108–16PubMedCrossRef
35.
Tran CP, Cook GA, Yeomans ND, Thim L, Giraud AS (1999) Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis. Gut 44:636–42PubMedCrossRef
36.
Carrasco R, Pera M, May FE, Westley BR, Martinez A, Morales L (2004) Trefoil factor family peptide 3 prevents the development and promotes healing of ischemia–reperfusion injury in weanling rats. J Pediatr Surg 39:1693–700PubMedCrossRef
37.
Mashimo H, Wu DC, Podolsky DK, Fishman MC (1996) Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 274:262–5PubMedCrossRef
38.
Poulsen SS, Thulesen J, Hartmann B, Kissow HL, Nexø E, Thim L (2003) Injected TFF1 and TFF3 bind to TFF2-immunoreactive cells in the gastrointestinal tract in rats. Regul Pept 115:91–9PubMedCrossRef
39.
Liu D, el-Hariry I, Karayiannakis AJ, Wilding J, Chinery R, Kmiot W, McCrea PD, Gullick WJ, Pignatelli M (1997) Phosphorylation of beta-catenin and epidermal growth factor receptor by intestinal trefoil factor. Lab Invest 77:557–63PubMed
40.
Lalani EN, Williams R, Jayaram Y, Gilbert C, Chaudhary KS, Siu LS, Koumarianou A, Playford R, Stamp GW (1999) Trefoil factor-2, human spasmolytic polypeptide, promotes branching morphogenesis in MCF-7 cells. Lab Invest 79:537–46PubMed
41.
Rodrigues S, Van Aken E, Van Bocxlaer S, Attoub S, Nguyen QD, Bruyneel E, Westley BR, May FE, Thim L, Mareel M, Gespach C, Emami S (2003) Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling. FASEB J 17:7–16PubMedCrossRef
42.
Storesund T, Hayashi K, Kolltveit KM, Bryne M, Schenck K (2008) Salivary trefoil factor 3 enhances migration of oral keratinocytes. Eur J Oral Sci 116:135–40PubMedCrossRef
43.
Storesund T, Schenck K, Osmundsen H, Røed A, Helgeland K, Kolltveit KM (2009) Signal transduction and gene transcription induced by TFF3 in oral keratinocytes. Eur J Oral Sci 117:511–7PubMedCrossRef
44.
Perry JK, Kannan N, Grandison PM, Mitchell MD, Lobie PE (2008) Are trefoil factors oncogenic? Trends Endocrinol Metab 19:74–81PubMedCrossRef
45.
Vestergaard EM, Borre M, Poulsen SS, Nexø E, Tørring N (2006) Plasma levels of trefoil factors are increased in patients with advanced prostate cancer. Clin Cancer Res 12:807–12PubMedCrossRef
46.
Emami S, Rodrigues S, Rodrigue CM, Le Floch N, Rivat C, Attoub S, Bruyneel E, Gespach C (2004) Trefoil factor family (TFF) peptides and cancer progression. Peptides 25:885–98PubMedCrossRef
47.
Samson MH, Chaiyarit P, Nortvig H, Vestergaad EM, Ernst E, Nexø E (2011) Trefoil factor family peptides in human saliva and in cyclical cervical mucus. Method evaluation and results on healthy individuals. Clin Chem Lab Med 49. doi:10.​1515/​CCLM.​2011.​123
48.
Taupin D, Pedersen J, Familari M, Cook G, Yeomans N, Giraud AS (2001) Augmented intestinal trefoil factor (TFF3) and loss of pS2 (TFF1) expression precedes metaplastic differentiation of gastric epithelium. Lab Invest 81:397–408PubMedCrossRef
49.
Taupin DR, Pang KC, Green SP, Giraud AS (1995) The trefoil peptides spasmolytic polypeptide and intestinal trefoil factor are major secretory products of the rat gut. Peptides 16:1001–5PubMedCrossRef
50.
Verey F, Nexø E, Greenwood R, Berry M, Corfield AP (2011) Trefoil factor family peptides are increased in the saliva of children with mucositis. Clin Chem Lab Med. doi:10.​1515/​CCLM.​2011.​667
51.
Regalo G, Wright NA, Machado JC (2005) Trefoil factors: from ulceration to neoplasia. Cell Mol Life Sci 62:2910–15PubMedCrossRef
52.
Peterson AJ, Menheniott TR, O'Connor L, Walduck AK, Fox JG, Kawakami K, Minamoto T, Ong EK, Wang TC, Judd LM, Giraud AS (2010) Helicobacter pylori infection methylates and silences trefoil factor 2 leading to gastric tumor development in mice and humans. Gastroenterology 139:2005–17PubMedCrossRef
Metadata
Title
Investigation of trefoil factor expression in saliva and oral mucosal tissues of patients with oral squamous cell carcinoma
Authors
Ponlatham Chaiyarit
Akasith Utrawichian
Chanvit Leelayuwat
Patrawut Vatanasapt
Nattharee Chanchareonsook
Mie Hessellund Samson
Andrew S. Giraud
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
Clinical Oral Investigations / Issue 6/2012
Print ISSN: 1432-6981
Electronic ISSN: 1436-3771
DOI
https://doi.org/10.1007/s00784-011-0667-z

Other articles of this Issue 6/2012

Clinical Oral Investigations 6/2012 Go to the issue

Original Article

Effect of radiation dose on the prevalence of apical periodontitis—a dosimetric analysis

Original Article

Relation between insertion torque and bone–implant contact percentage: an artificial bone study

Original Article

Case–control study on the survival of abutment teeth of partially dentate patients

Original Article

Long-term outcome of primary non-surgical root canal treatment

Letter to the Editor

Design and analytical issues: a response to “Long-term effects of tongue piercing—a case control study”

Letter to the Editor

On hematological features in adolescents with periodontitis